Testing CTx001 for geographic atrophy (GA) in AMD
Part of Eyes & vision clinical trials.
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have geographic atrophy (GA) in both eyes from age-related macular degeneration (AMD).
- Your eyesight and retinal details meet the study's specific measurements (like visual acuity, low-light vision, and retinal sensitivity).
- You have not had prior treatments for AMD or other eye conditions that could interfere with the study (e.g., wet AMD, certain surgeries, or complement inhibitor therapy).
- You are able to have regular eye imaging and follow the study procedures, and you meet age and reproductive health rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
This trial tests an oral medication called BRX011 for people with geographic atrophy (a form of advanced dry age-related macular degeneration). The goal is to see if it is safe and can help slow vision loss.
This trial tests a single gene therapy injection (AGX-08) for people with advanced geographic atrophy, a severe form of age-related macular degeneration that causes vision loss. It aims to see if the treatment is safe and can slow down further damage.
Hear when a new Geographic Atrophy Secondary to Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.